Ultrasus-guided thoracic paravertebral nerve block: Comparison of analgesic effects of drugs administered at different thoracic levels

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093559

Enrollment

Unknown

Registered

2024-12-06

Start date

2024-12-07

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung disease

Interventions

T2 group:Thoracic paravertebral nerve block at the T2 level

T4 group:Thoracic paravertebral nerve block at the T4 level

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing selective thoracoscopic partial pulmonary resection in our hospital; 2.ASA grade I to III, aged between 18 and 75 years; 3.No TPVB contraindication; 4.No contraindications for thoracoscopy; 5.Patients who voluntarily accepted the VAS pain score should understand the principle of VAS pain score and pain evaluation; 6.No chronic pain; 7.Good tolerance to anesthesia.

Exclusion criteria

Exclusion criteria: 1.Patients with severe cardiovascular, liver and kidney diseases; 2.Combined with metabolic or endocrine diseases; 3.Puncture site infection or thoracic or spinal malformations; 4.Those who are receiving antiplatelet drug therapy; 5.Body mass index greater than 35kg/m^2; 6.Mental illness, unable to cooperate with researchers; 7.Allergic to local amide anesthetics, long-term use of antipsychotic drugs; 8.People who have a history of allergy to narcotic drugs and refuse to use analgesic pumps;

Design outcomes

Primary

Measure	Time frame
Visual analogue score (VAS) of patients at rest and in active state within 24h after surgery;	—

Secondary

Measure	Time frame
Mean arterial pressure (MAP) and heart rate (HR) at different time points during the operation;Drug dosage(Total intraoperative sufentanil dosage, total propofol dosage, and sufentanil dosage during PACU);Duration of first controlled analgesia (PCA) and number of compressions after TPVB;The number of analgesic remedies in each group;Retarding plane range;Occurrence of adverse events(Nausea and vomiting, postoperative puncture site hematoma, pneumothorax, infection and other block-related adverse events);	—

Measure

Time frame

Mean arterial pressure (MAP) and heart rate (HR) at different time points during the operation;Drug dosage(Total intraoperative sufentanil dosage, total propofol dosage, and sufentanil dosage during PACU);Duration of first controlled analgesia (PCA) and number of compressions after TPVB;The number of analgesic remedies in each group;Retarding plane range;Occurrence of adverse events(Nausea and vomiting, postoperative puncture site hematoma, pneumothorax, infection and other block-related adverse events);

—

Countries

China

Contacts

Public ContactShiyong Teng

First Hospital of Jilin University

warriorteng@126.com+86 150 4410 7637

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026